Hookipa Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.681
- Today's High:
- $0.709
- Open Price:
- $0.709
- 52W Low:
- $0.62
- 52W High:
- $2.05
- Prev. Close:
- $0.685
- Volume:
- 152535
Company Statistics
- Market Cap.:
- $57.17 million
- Book Value:
- 1.338
- Revenue TTM:
- $15.91 million
- Operating Margin TTM:
- -494.63%
- Gross Profit TTM:
- $-52966000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.08%
- Return on Equity TTM:
- -55.91%
Company Profile
Hookipa Pharma Inc had its IPO on 2019-04-18 under the ticker symbol HOOK.
The company operates in the Healthcare sector and Biotechnology industry. Hookipa Pharma Inc has a staff strength of 156 employees.
Stock update
Shares of Hookipa Pharma Inc opened at $0.71 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.68 - $0.71, and closed at $0.69.
This is a +0.07% increase from the previous day's closing price.
A total volume of 152,535 shares were traded at the close of the day’s session.
In the last one week, shares of Hookipa Pharma Inc have increased by +0.66%.
Hookipa Pharma Inc's Key Ratios
Hookipa Pharma Inc has a market cap of $57.17 million, indicating a price to book ratio of 0.379 and a price to sales ratio of 4.1011.
In the last 12-months Hookipa Pharma Inc’s revenue was $15.91 million with a gross profit of $-52966000 and an EBITDA of $-75259000. The EBITDA ratio measures Hookipa Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Hookipa Pharma Inc’s operating margin was -494.63% while its return on assets stood at -27.08% with a return of equity of -55.91%.
In Q2, Hookipa Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 2.4%.
Hookipa Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.9 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Hookipa Pharma Inc’s profitability.
Hookipa Pharma Inc stock is trading at a EV to sales ratio of 1.9077 and a EV to EBITDA ratio of 0.7323. Its price to sales ratio in the trailing 12-months stood at 4.1011.
Hookipa Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $191.11 million
- Total Liabilities
- $46.25 million
- Operating Cash Flow
- $-445000.00
- Capital Expenditure
- $445000
- Dividend Payout Ratio
- 0%
Hookipa Pharma Inc ended 2024 with $191.11 million in total assets and $0 in total liabilities. Its intangible assets were valued at $191.11 million while shareholder equity stood at $112.33 million.
Hookipa Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $46.25 million in other current liabilities, 8000.00 in common stock, $-325377000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $135.59 million and cash and short-term investments were $135.59 million. The company’s total short-term debt was $2,628,000 while long-term debt stood at $0.
Hookipa Pharma Inc’s total current assets stands at $168.14 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $20.46 million compared to accounts payable of $11.65 million and inventory worth $0.
In 2024, Hookipa Pharma Inc's operating cash flow was $-445000.00 while its capital expenditure stood at $445000.
Comparatively, Hookipa Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.69
- 52-Week High
- $2.05
- 52-Week Low
- $0.62
- Analyst Target Price
- $4.28
Hookipa Pharma Inc stock is currently trading at $0.69 per share. It touched a 52-week high of $2.05 and a 52-week low of $2.05. Analysts tracking the stock have a 12-month average target price of $4.28.
Its 50-day moving average was $0.76 and 200-day moving average was $0.92 The short ratio stood at 0.49 indicating a short percent outstanding of 0%.
Around 501.2% of the company’s stock are held by insiders while 4058.4% are held by institutions.
Frequently Asked Questions About Hookipa Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company’s preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.